Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
Recurrent glioblastomas (rGBM) have dismal outcomes, but long-term survival has been observed in subsets of patients after immunotherapy. Here the authors report a positive association between low tumor mutation burden, inflammatory gene signatures, and survival after immunotherapy in rGBM patients.
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9b4f7304b8f54613b5f0b6626698e589 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9b4f7304b8f54613b5f0b6626698e589 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9b4f7304b8f54613b5f0b6626698e5892021-12-02T15:22:48ZVery low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy10.1038/s41467-020-20469-62041-1723https://doaj.org/article/9b4f7304b8f54613b5f0b6626698e5892021-01-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-20469-6https://doaj.org/toc/2041-1723Recurrent glioblastomas (rGBM) have dismal outcomes, but long-term survival has been observed in subsets of patients after immunotherapy. Here the authors report a positive association between low tumor mutation burden, inflammatory gene signatures, and survival after immunotherapy in rGBM patients.Matthias GromeierMichael C. BrownGao ZhangXiang LinYeqing ChenZhi WeiNike BeaubierHai YanYiping HeAnnick DesjardinsJames E. HerndonFrederick S. VarnRoel G. VerhaakJunfei ZhaoDani P. BolognesiAllan H. FriedmanHenry S. FriedmanFrances McSherryAndrea M. MuscatEric S. LippSmita K. NairMustafa KhasrawKatherine B. PetersDina RandazzoJohn H. SampsonRoger E. McLendonDarell D. BignerDavid M. AshleyNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-7 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Science Q |
| spellingShingle |
Science Q Matthias Gromeier Michael C. Brown Gao Zhang Xiang Lin Yeqing Chen Zhi Wei Nike Beaubier Hai Yan Yiping He Annick Desjardins James E. Herndon Frederick S. Varn Roel G. Verhaak Junfei Zhao Dani P. Bolognesi Allan H. Friedman Henry S. Friedman Frances McSherry Andrea M. Muscat Eric S. Lipp Smita K. Nair Mustafa Khasraw Katherine B. Peters Dina Randazzo John H. Sampson Roger E. McLendon Darell D. Bigner David M. Ashley Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy |
| description |
Recurrent glioblastomas (rGBM) have dismal outcomes, but long-term survival has been observed in subsets of patients after immunotherapy. Here the authors report a positive association between low tumor mutation burden, inflammatory gene signatures, and survival after immunotherapy in rGBM patients. |
| format |
article |
| author |
Matthias Gromeier Michael C. Brown Gao Zhang Xiang Lin Yeqing Chen Zhi Wei Nike Beaubier Hai Yan Yiping He Annick Desjardins James E. Herndon Frederick S. Varn Roel G. Verhaak Junfei Zhao Dani P. Bolognesi Allan H. Friedman Henry S. Friedman Frances McSherry Andrea M. Muscat Eric S. Lipp Smita K. Nair Mustafa Khasraw Katherine B. Peters Dina Randazzo John H. Sampson Roger E. McLendon Darell D. Bigner David M. Ashley |
| author_facet |
Matthias Gromeier Michael C. Brown Gao Zhang Xiang Lin Yeqing Chen Zhi Wei Nike Beaubier Hai Yan Yiping He Annick Desjardins James E. Herndon Frederick S. Varn Roel G. Verhaak Junfei Zhao Dani P. Bolognesi Allan H. Friedman Henry S. Friedman Frances McSherry Andrea M. Muscat Eric S. Lipp Smita K. Nair Mustafa Khasraw Katherine B. Peters Dina Randazzo John H. Sampson Roger E. McLendon Darell D. Bigner David M. Ashley |
| author_sort |
Matthias Gromeier |
| title |
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy |
| title_short |
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy |
| title_full |
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy |
| title_fullStr |
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy |
| title_full_unstemmed |
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy |
| title_sort |
very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/9b4f7304b8f54613b5f0b6626698e589 |
| work_keys_str_mv |
AT matthiasgromeier verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT michaelcbrown verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT gaozhang verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT xianglin verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT yeqingchen verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT zhiwei verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT nikebeaubier verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT haiyan verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT yipinghe verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT annickdesjardins verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT jameseherndon verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT fredericksvarn verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT roelgverhaak verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT junfeizhao verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT danipbolognesi verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT allanhfriedman verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT henrysfriedman verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT francesmcsherry verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT andreammuscat verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT ericslipp verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT smitaknair verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT mustafakhasraw verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT katherinebpeters verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT dinarandazzo verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT johnhsampson verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT rogeremclendon verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT darelldbigner verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT davidmashley verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy |
| _version_ |
1718387393120174080 |